KCNK3 and pulmonary arterial hypertension: As KCNK3 dysfunction can play a significant role in the pathogenesis of PAH, there is great interest in developing selective pharmacologic agents to block and activate the channel, for experimental and therapeutic purposes, respectively (Figure 1).